Wall Street Zen downgraded shares of Grace Therapeutics (NASDAQ:GRCE – Free Report) from a sell rating to a strong sell rating in a research note released on Saturday morning,Wall Street Zen reports.
A number of other analysts have also commented on the company. Weiss Ratings restated a “sell (d-)” rating on shares of Grace Therapeutics in a report on Thursday, October 15th. Zacks Research raised Grace Therapeutics to a “hold” rating in a research report on Monday, August 3rd. One investment analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Grace Therapeutics currently has an average rating of “Hold” and a consensus price target of $6.00.
View Our Latest Analysis on GRCE
Grace Therapeutics Stock Up 0.8%
Shares of GRCE stock opened at $1.86 on Friday. Grace Therapeutics has a 12-month low of $1.67 and a 12-month high of $5.18. The firm has a fifty day moving average of $2.03 and a 200-day moving average of $2.78. The company has a market capitalization of $39.24 million, a price-to-earnings ratio of -1.58 and a beta of 0.43.
Grace Therapeutics (NASDAQ:GRCE – Get Free Report) last posted its quarterly earnings data on Friday, August 14th. The company reported ($0.91) EPS for the quarter, missing the consensus estimate of ($0.13) by ($0.78). During the same quarter last year, the company earned ($0.21) EPS.
Hedge Funds Weigh In On Grace Therapeutics
Institutional investors have recently added to or reduced their stakes in the company. Stonepine Capital Management LLC bought a new stake in Grace Therapeutics during the second quarter worth $62,125,000. Eversept Partners LP acquired a new stake in shares of Grace Therapeutics in the first quarter valued at approximately $3,503,000. Renaissance Technologies LLC boosted its stake in shares of Grace Therapeutics by 87.9% during the 1st quarter. Renaissance Technologies LLC now owns 243,910 shares of the company’s stock worth $1,129,000 after acquiring an additional 114,129 shares during the period. Bank of America Corp DE acquired a new stake in shares of Grace Therapeutics during the 2nd quarter worth about $1,123,000. Finally, Maven Securities LTD acquired a new stake in shares of Grace Therapeutics during the 2nd quarter worth about $454,000. 6.08% of the stock is currently owned by institutional investors and hedge funds.
Grace Therapeutics Company Profile
Grace Therapeutics, Inc (NASDAQ: GRCE) is a clinical-stage biopharmaceutical company developing therapies for rare and life-threatening medical conditions. The company focuses on drug-delivery technologies intended to improve the administration, absorption, and therapeutic performance of established pharmaceutical compounds.
Grace Therapeutics’ lead candidate is GTx-104, an investigational injectable formulation of nimodipine being developed for patients with aneurysmal subarachnoid hemorrhage, a serious form of bleeding around the brain.
Further Reading
- Five stocks we like better than Grace Therapeutics
- Wall Street May Be Making a Big Mistake With monday.com Stock
- Are These 2 Mid-Cap Growth Stocks Worth the Risk?
- Oklo Changes the Narrative: Does a Nuclear Stock Price Explosion Come Next?
- Cloudflare’s 20% Sell-Off May Have Created an Opening for Investors
Receive News & Ratings for Grace Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Grace Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
